Use of anticonvulsive drugs during pregnancy and the risk of malformations in the newborn: A meta-analysis;Uso de anticonvulsionantes durante el embarazo y riesgo de malformaciones en el recién nacido: Metanálisis

Revista de Neurologia

Volumn 37, Issue 11, 2003, Pages 1022-1028

  Gutiérrez Álvarez, Ángela María ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

Anticonvulsants; Epidemiology; Meta analysis; Odds ratio; Pregnancy complications; Prenatal exposure delayed effects

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ARTICLE; CARDIOVASCULAR MALFORMATION; CENTRAL NERVOUS SYSTEM MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DIGESTIVE SYSTEM MALFORMATION; EMBASE; EPILEPSY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; PREGNANCY; PRENATAL EXPOSURE; SCISEARCH; SKELETON MALFORMATION; TERATOGENICITY; URINARY TRACT MALFORMATION;

EID: 0347753308     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3711.2003292     Document Type: Article

References (69)

1. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota, 1940-1980. Epilepsia 1991; 32: 429-45.
2. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986; 1: 1392-3.
3. Janz D. Are anti epileptic drugs harmful when taken during pregnancy? J Perinat Med 1994; 22: 367-77.
4. Janz D. The teratogenic risk of antiepileptic drugs. Epilepsia 1975; 16: 159-69.
5. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40: 1231-6.
6. Sharony R, Graham JM. Identification of fetal problems associated with anticonvulsants usage and maternal epilepsy. Obstet Gynecol Clin North Am 1991; 18: 933-51.
7. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2: 839-43.
8. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975; 87: 285-90.
9. Hill RM, Verniaud WM, Horning MG, McCulley LB, Morgan NF. Infants exposed in utero to antiepileptic drugs. Am J Dis Child 1974; 127: 645-53.
10. Hanson JW, Myrianthopoulos NC, Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants with emphasis on the fetal hydantoin syndrome. J Pediatr 1976; 89: 662-8.
11. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661-6.
12. Lindhout D, Hoppener RJ, Meinard H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984; 25: 77-83.
13. Seip M. Growth retardation, dysmorphic facies and minor malformations following massive exposure to phenobarbitone in utero. Acta Paediatr Scand 1976; 65: 617-21.
14. Bennet JC, Plum F. Cecil textbook of medicine. 20 ed. Vol. 2. Philadelphia: WB Saunders; 1995. p. 2123
15. Barron WM, Lindheimer MD. Medical disorders during pregnancy. 2 ed. St. Louis: Mosby-Year Book; 1994. p. 443
16. Dalessio DJ. Seizures disorders and pregnancy. N Engl J Med 1985; 312: 559-63.
17. Gaily E, Granstrom ML, Hillesmaa V, Bardy A. Minor anomalies in offspring of epileptic mothers. J Pediatr 1988; 112: 520-9.
18. Monson RR, Rosenberg L, Hartz SC, Shapiro S, Heinonen OP, Slone D. Diphenylhydantoin and selected congenital malformations. N Engl J Med 1973; 289: 1049-52.
19. Schmidt D, Canger R, Avanzini G, Battino D, Cusi C, Beck-Mannagetta G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983; 46: 751-5.
20. Knight AH, Rhind EG. Epilepsy and pregnancy: A study of 153 pregnancies in 59 patients. Epilepsia 1975; 16: 99-110.
21. Lindhout D, Omtzigt JGC. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35 (Suppl 4): S19-28.
22. Stumpf DA, Frost M. Seizures, anticonvulsants and pregnacy. Am J Dis Child 1978; 132: 746-8.
23. Teramo K, Hiilesmaa V, Bardy A, Saarihosk S. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7: 3-6.
24. Yerby MS. Problems and management of the pregnant woman with epilepsy. Epilepsia 1987; 28 (Suppl 3): S29-36.
25. Strickler SM, Dansky LV, Miller MA, Seni MH, Andermann E, Spielberg SP. Genetic predisposition to phenytoin induced birth defects. Lancet 1985; 2: 746-9.
26. Licht EA, Sankar R. Status epilepticus during pregnancy: a case report. J Reprod Med 1999; 44: 370-2.
27. Friis ML. Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurol Scand 1989; 79: 433-59.
28. Friis ML, Holm NV, Sindrup EH, Fogh-Andersen P, Hauge M. Facial clefts in sibs and children of epileptic patients. Neurology 1986; 36: 346-50.
29. Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000; 41: 107-39.
30. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V. User's guides to the medical literature. IV. How to use an article about harm. JAMA 1994; 271: 1615-9.
31. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2: 839-43.
32. Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. Br Med J 1973; 2: 442-8.
33. Bjerkedal T, Bahna SL. The course and outcome of pregnancy in women with epilepsy. Acta Obstet Gynecol Scand 1973; 52: 245-8.
34. Jager-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108: 997-1004.
35. Martínez-Frias ML. Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information. Am J Med Genet 1990; 37: 277-82.
36. Tanganelli P, Regesta G. Epilepsy, pregnancy, and major anomalies: an Italian prospective, controlled study. Neurology 1992; 42 (Suppl 5): 89-93.
37. Czeizel AE, Bod M, Halasz P. Evaluation of anticonvulsant drug during pregnancy in a population-based Hungarian study. Eur J Epidemiol 1992; 8: 122-7.
38. Dravet C, Julian C, Legras C, Magaudda A, Guerrini R, et al. Epilepsy, antiepileptic drugs and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42 (Suppl 5): 75-82.
39. Waters CH, Belai Y, Gott PS, Shen P, De Giorgio CM. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994; 51: 250-3.
40. Steegers-Theunissen RP, Renier WO, Borm GF, Thomas CMG, Merkus HM, Op de Coul DAW, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Res 1994; 18: 261-9.
41. Sabers A, Rogvi-Hansen B, Dam M, Fisher-Rasmussen W, Gram L, Hansen M, et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta Neurol Scand 1998; 97: 164-70.
42. Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998; 39: 887-92.
43. Fonager K, Larsen H, Pedersen L, Sorensen HT. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 2000; 101: 289-94.
44. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-8.
45. Sawhney H, Vasishta K, Suri V, Khunnu B, Goel P, Sawhney IM. Pregnancy with epilepsy: a retrospective analysis. Int J Gynaecol Obstet 1996; 54: 17-22.
46. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner HA, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271: 767-70 [Erratum in: JAMA 1994; 271: 1745].
47. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner HA, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271: 767-70 [Erratum in: JAMA 1994; 271: 1745].
48. Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001; 57: 321-4.
49. Meyer JG. The teratological effects of anticonvulsants and the effects on pregnancy and birth. Eur Neurol 1973; 10: 179-90.
50. Annegers JF, Elveback LR, Hauser WA, Kurland LT. Do anticonvulsants have a teratogenic effect? Arch Neurol 1974; 31: 364-73.
51. Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T, Sato T, et al. Multi-institutional study on the teratogenicity and fetal toxicity of anti-epileptic drugs: Report of a collaborative study group in Japan. Epilepsia 1980; 21: 663-80.
52. Monson R, Rosenberg L, Hartz S, Shapiro S, Heinonen OP, Slone D. Diphenylhydantoin and selected congenital malformations. N Engl J Med 1973; 289: 1049-52.
53. South J. Teratogenic effects of anticonvulsants. Lancet 1972; 2: 1154.
54. Lowe CR. Congenital malformations among infants born to epileptic women. Lancet 1973; 1: 9-10.
55. Annegers JF, Hauser W, Elveback LR, Anderson VE, Kurland T. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978; 7: 241-7.
56. Koch S, Losche G, Jager-Roman E, Jacob S, Rating D, Deichl A, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992; 42 (Suppl 5): 83-8.
57. Meyer JG. The teratological effects of anticonvulsants and the effects on pregnancy and birth. Eur Neurol 1973; 10: 179-90.
58. Bjerkedal T, Bahna SL. The course and outcome of pregnancy in women with epilepsy. Acta Obstet Gynecol Scand 1973; 52: 245-8.
59. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37: 1242-4.
60. Stelmasiak Z, Semczuk W, Nowicka-Tarach B, Halczuk I, Semczuk-Sikora A, Laskowska M. Analysis of epileptic pregnant women delivering between 1992-1998 in obstetric departments of the University Medical School in Lublin. Neurol Neurochir Pol 2002; 36: 1245-8.
61. Petitti DB. Meta-analysis. Decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in Medicine. Oxford: Oxford University Press; 1994. p. 91-114.
62. Lander CM, Eadie MJ. Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990; 7: 77-82.
63. Dansky LV, Rosenblatt DS, Anderman E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992; 42 (Suppl 5): 32-42.
64. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996; 75: 517-20.
65. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608-14.
66. Janz D, Dam M, Reichens A, Bossi L, Hege H, Schmidt D. A: pregnancy and fetal complications in epileptic pregnancies: review of the literature. B: outcome of pregnancy in women with epilepsy, Norway 1967-1978. In Janz D, Bossi L, Dam M, eds. Epilepsy, pregnancy and the child. New York: Raven Press; 1982. p. 53-69.
67. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674-7.
68. Friis ML, Hauge M. Congenital heart defects in live-born children of epileptic parents. Arch Neurol 1985; 42: 374-6.
69. Jacobs MP, Fischbach GD, Davis MR, Dichter MA, Dingledine R, Lowenstein DH, et al. Future directions for epilepsy research. Neurology 2001; 57: 1536-42.